Ozempic for Weight Loss — What It Does to Your Liver

Ozempic contains semaglutide at doses up to 1mg weekly. Wegovy contains the same molecule at 2.4mg — the dose TGA-approved specifically for weight management and MASH treatment. Many GPs prescribe Ozempic for weight loss because it is PBS-subsidised for patients with type 2 diabetes, or because Wegovy stock and cost create barriers.

Using Ozempic for weight loss is common clinical practice but technically off-label when prescribed to patients without type 2 diabetes. If your primary goal is weight management without diabetes, discuss whether Wegovy or Mounjaro may be more appropriate — they are TGA-approved for this indication and may produce greater weight loss.

Regardless of which semaglutide formulation you take, the liver effects follow the same pathway: weight loss drives liver fat reduction, and GLP-1 receptor activation provides additional metabolic benefits in hepatic tissue.

Compare Ozempic, Mounjaro and Wegovy →

Clinical trials show semaglutide 1mg (Ozempic) produces approximately 10–14% body weight reduction at 68–72 weeks. Semaglutide 2.4mg (Wegovy) achieves approximately 14–17%. Tirzepatide (Mounjaro) achieves approximately 20% in head-to-head comparison.

For liver health, the threshold that matters most is 7–10% weight loss — the point at which significant liver fat reduction occurs in MASLD. Most patients on Ozempic reach this threshold if they remain on treatment for 6–12 months.

Weight loss of 10% or more is associated with MASH resolution in many patients. Ozempic at 1mg may not reach this threshold in all patients — which is one reason Wegovy at 2.4mg was studied specifically for MASH in the ESSENCE trial (62.9% MASH resolution at 72 weeks).

Ozempic vs Mounjaro — weight loss comparison →

When you lose weight on Ozempic, your liver is one of the first organs to benefit. Excess fat stored in liver cells (hepatic steatosis) is mobilised as overall body fat decreases. Liver enzymes — ALT and AST — often normalise as inflammation reduces.

Approximately 30% of Australian adults have MASLD (fatty liver disease). The condition is closely linked to obesity, type 2 diabetes, and metabolic syndrome — the same profile as many Ozempic patients. If you had fatty liver before starting Ozempic, weight loss on the medication is likely improving it.

If you did not know you had fatty liver before starting Ozempic, you may still have it. MASLD is usually silent — no symptoms until advanced stages. This is why baseline liver assessment is recommended, not because Ozempic is dangerous, but because undiagnosed fibrosis should be identified and monitored.

Ozempic and fatty liver — full guide →

Fatty liver disease in Australia →

The MJA September 2025 consensus statement recommends MASLD assessment for all GLP-1 patients with metabolic risk factors. If you are taking Ozempic for weight loss and you have obesity, type 2 diabetes, or metabolic syndrome, you meet this criteria.

The concern is not that Ozempic damages the liver — the evidence shows the opposite. The concern is that significant liver fibrosis (F2–F3) may be present without symptoms, and treatment decisions differ depending on fibrosis stage:

• Simple fatty liver (steatosis only): lifestyle and weight loss on Ozempic is usually sufficient
• MASH with F2–F3 fibrosis: Wegovy 2.4mg is now TGA-approved; specialist monitoring required
• Cirrhosis (F4): different treatment pathway; Wegovy MASH indication excludes cirrhotic patients

Without baseline assessment, you cannot know which category you are in. A FIB-4 score from routine blood tests takes seconds and costs nothing extra if bloods are already being done.

Some patients notice their liver enzymes (ALT, AST) rise temporarily during the first 8–12 weeks of Ozempic treatment, particularly during rapid initial weight loss. This can be alarming but is usually benign.

The mechanism: as body fat is mobilised rapidly, fatty acids flood the liver temporarily before being exported. This transient hepatic fat overload can elevate enzymes without indicating liver damage. Enzymes typically normalise as weight loss stabilises and the rate of fat mobilisation slows.

Your GP should repeat liver function tests at 3 months. If enzymes remain elevated or rise further, further investigation with elastography is appropriate to exclude underlying MASH or other liver pathology unrelated to Ozempic.

This pattern is common to all GLP-1 medications and rapid weight loss generally — it is not specific to Ozempic and does not indicate the medication is harming your liver.

GLP-1 medications increase gallstone risk by approximately 27% compared to non-GLP-1 users. Rapid weight loss independently increases gallstone formation. The combination creates a meaningful risk during the first 6–12 months of Ozempic treatment.

Gallstones matter for liver health because complicated gallstone disease can cause cholestasis (bile flow obstruction), acute cholangitis, and gallstone pancreatitis — all of which affect the liver and require emergency treatment.

Watch for right upper abdominal pain (particularly after eating fatty foods), pain radiating to the right shoulder, nausea, vomiting, and fever. Seek urgent medical care if these symptoms develop.

GLP-1 medications and gallstones — full guide →

Consider liver elastography (FibroScan or guided transient elastography) if any of the following apply:

• You are starting Ozempic for weight loss and have never had liver health assessed
• Your FIB-4 score is indeterminate (1.3–2.67) or high (>2.67)
• Your liver enzymes remain elevated at 3-month follow-up
• You have type 2 diabetes, obesity (BMI >30), or metabolic syndrome
• You have been on Ozempic for 12 months and want to assess treatment response

Liver elastography takes 10–15 minutes, involves no radiation, and costs approximately $150–$300 at private Australian clinics. Results are available immediately. Several clinics accept self-referral.

A liver stiffness below 8 kPa is reassuring. Stiffness 8–13 kPa suggests significant fibrosis warranting specialist review. Above 13 kPa is in the cirrhosis range and requires urgent hepatology referral.

FibroScan in Australia — what to expect →

Find a liver elastography clinic near you →

Before booking a liver scan, ask your GP to calculate your FIB-4 score from your most recent blood test. FIB-4 uses age, ALT, AST, and platelet count — all available from a standard blood panel.

1. FIB-4 below 1.3: low risk — reassured, repeat in 3 years
2. FIB-4 1.3–2.67: indeterminate — book elastography
3. FIB-4 above 2.67: high risk — specialist referral recommended

If you are already on Ozempic and having regular blood tests for diabetes monitoring, your GP likely already has the data needed to calculate FIB-4. Ask at your next appointment.

Can Ozempic treat fatty liver? →